SIMILAR PATTERNS OF AMINO ACIDS FOR 4HJO_A_AQ4A1001_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 428 LYS A 430 THR A 474 MET A 477 GLY A 480 LEU A 528 ASP A 539	None	0.96A	4hjoA-1k2pA: 30.0	4hjoA-1k2pA: 32.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 428 THR A 474 MET A 477 GLY A 480 CYH A 481 LEU A 528 ASP A 539	None	0.68A	4hjoA-1k2pA: 30.0	4hjoA-1k2pA: 32.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 408 VAL A 416 LYS A 430 MET A 477 GLY A 480 LEU A 528 ASP A 539	None	1.10A	4hjoA-1k2pA: 30.0	4hjoA-1k2pA: 32.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 408 VAL A 416 MET A 477 GLY A 480 CYH A 481 LEU A 528 ASP A 539	None	0.97A	4hjoA-1k2pA: 30.0	4hjoA-1k2pA: 32.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 416 ALA A 428 LYS A 430 MET A 477 GLY A 480 LEU A 528 ASP A 539	None	0.99A	4hjoA-1k2pA: 30.0	4hjoA-1k2pA: 32.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 416 ALA A 428 MET A 477 GLY A 480 CYH A 481 LEU A 528 ASP A 539	None	0.87A	4hjoA-1k2pA: 30.0	4hjoA-1k2pA: 32.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	ALA A 220 LYS A 222 THR A 266 MET A 269 GLY A 272 LEU A 321 ASP A 332	None	0.92A	4hjoA-1k9aA: 30.5	4hjoA-1k9aA: 26.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	VAL A 209 ALA A 220 THR A 266 MET A 269 GLY A 272 LEU A 321 ASP A 332	None	0.66A	4hjoA-1k9aA: 30.5	4hjoA-1k9aA: 26.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 267 VAL A 275 ALA A 288 LYS A 290 THR A 334 MET A 337 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-3.7A) None P16 A 2 (-4.4A)	0.67A	4hjoA-1opkA: 29.7	4hjoA-1opkA: 25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 267 VAL A 275 ALA A 288 THR A 334 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-3.7A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.63A	4hjoA-1opkA: 29.7	4hjoA-1opkA: 25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 78 VAL A 86 ALA A 99 LYS A 101 MET A 150 GLY A 153 LEU A 201 ASP A 212	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) None ATP A 535 ( 4.7A) ATP A 535 (-4.8A) MG A 536 (-3.3A)	0.52A	4hjoA-1s9iA: 9.1	4hjoA-1s9iA: 26.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 377 ALA A 389 LYS A 391 GLY A 441 CYH A 442 LEU A 489 ASP A 500	None	0.81A	4hjoA-1snxA: 31.4	4hjoA-1snxA: 31.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 377 ALA A 389 LYS A 391 MET A 438 GLY A 441 CYH A 442 LEU A 489	None	0.71A	4hjoA-1snxA: 31.4	4hjoA-1snxA: 31.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 595 VAL A 603 ALA A 621 LYS A 623 THR A 670 GLY A 676 LEU A 799	STI A 3 ( 3.8A) STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 (-3.7A) STI A 3 (-3.2A) STI A 3 ( 3.8A) STI A 3 (-4.4A)	0.68A	4hjoA-1t46A: 25.4	4hjoA-1t46A: 31.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 15 VAL A 23 ALA A 36 LYS A 38 GLY A 90 LEU A 137 ASP A 148	HYM A 400 (-4.2A) HYM A 400 (-4.3A) HYM A 400 (-3.5A) HYM A 400 (-3.2A) None HYM A 400 (-4.5A) HYM A 400 (-3.9A)	0.91A	4hjoA-1zltA: 20.9	4hjoA-1zltA: 24.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU X 17 VAL X 25 ALA X 37 LYS X 39 MET X 85 LEU X 137 ASP X 148	STU X 902 (-3.8A) STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 (-3.1A) None STU X 902 (-4.4A) STU X 902 (-3.6A)	0.96A	4hjoA-2dq7X: 30.9	4hjoA-2dq7X: 32.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU X 17 VAL X 25 ALA X 37 LYS X 39 THR X 82 MET X 85 LEU X 137	STU X 902 (-3.8A) STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 (-3.1A) STU X 902 (-4.1A) None STU X 902 (-4.4A)	0.77A	4hjoA-2dq7X: 30.9	4hjoA-2dq7X: 32.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU X 17 VAL X 25 ALA X 37 MET X 85 GLY X 88 LEU X 137 ASP X 148	STU X 902 (-3.8A) STU X 902 ( 4.8A) STU X 902 (-3.1A) None STU X 902 (-3.5A) STU X 902 (-4.4A) STU X 902 (-3.6A)	0.65A	4hjoA-2dq7X: 30.9	4hjoA-2dq7X: 32.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU X 17 VAL X 25 ALA X 37 THR X 82 MET X 85 GLY X 88 LEU X 137	STU X 902 (-3.8A) STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 (-4.1A) None STU X 902 (-3.5A) STU X 902 (-4.4A)	0.53A	4hjoA-2dq7X: 30.9	4hjoA-2dq7X: 32.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	9	LEU A 273 VAL A 281 ALA A 293 LYS A 295 THR A 338 MET A 341 GLY A 344 LEU A 393 ASP A 404	H8H A 534 (-3.8A) H8H A 534 (-4.4A) H8H A 534 (-3.2A) H8H A 534 (-3.7A) H8H A 534 (-3.1A) None H8H A 534 (-3.3A) H8H A 534 (-4.5A) H8H A 534 (-4.2A)	0.47A	4hjoA-2h8hA: 35.5	4hjoA-2h8hA: 22.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	9	LEU A 273 VAL A 281 ALA A 293 LYS A 295 THR A 338 MET A 341 GLY A 344 LEU A 393 ASP A 404	QUE A 1 (-3.9A) QUE A 1 ( 4.8A) QUE A 1 (-3.5A) None QUE A 1 (-3.3A) None QUE A 1 (-3.0A) QUE A 1 (-4.4A) None	0.60A	4hjoA-2hckA: 32.7	4hjoA-2hckA: 26.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hen	EPHRIN TYPE-B RECEPTOR 2 (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 643 ALA A 659 LYS A 661 THR A 707 MET A 710 GLY A 713 LEU A 761	ADP A 400 ( 4.4A) ADP A 400 (-3.2A) ADP A 400 (-2.7A) ADP A 400 (-4.7A) None ADP A 400 ( 4.2A) ADP A 400 ( 4.7A)	0.74A	4hjoA-2henA: 30.1	4hjoA-2henA: 33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 251 VAL A 259 ALA A 271 THR A 316 MET A 319 GLY A 322 LEU A 371	1BM A 499 ( 3.7A) 1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) 1BM A 499 (-3.2A) None 1BM A 499 (-3.5A) 1BM A 499 (-4.4A)	0.35A	4hjoA-2hk5A: 29.9	4hjoA-2hk5A: 33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 248 VAL A 256 ALA A 269 LYS A 271 THR A 315 MET A 318 GLY A 321 LEU A 370	GIN A 600 ( 4.6A) GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-3.4A) None None GIN A 600 (-4.7A)	0.69A	4hjoA-2hz0A: 30.1	4hjoA-2hz0A: 35.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 251 ALA A 271 LYS A 273 THR A 316 MET A 319 GLY A 322 LEU A 371	None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 4.4A) 1N8 A 501 ( 3.5A) 1N8 A 501 ( 4.3A)	0.78A	4hjoA-2og8A: 29.1	4hjoA-2og8A: 33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 251 VAL A 259 ALA A 271 LYS A 273 THR A 316 MET A 319 GLY A 322	None None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 4.4A) 1N8 A 501 ( 3.5A)	0.80A	4hjoA-2og8A: 29.1	4hjoA-2og8A: 33.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	7	LEU A 344 VAL A 352 ALA A 367 LYS A 369 GLY A 418 LEU A 468 ASP A 479	ANP A 615 (-4.4A) ANP A 615 (-4.5A) ANP A 615 (-3.3A) ANP A 615 (-3.1A) ANP A 615 ( 4.0A) ANP A 615 (-4.7A) MG A 614 ( 3.2A)	1.13A	4hjoA-2ozoA: 31.3	4hjoA-2ozoA: 20.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	7	LEU A 344 VAL A 352 ALA A 367 LYS A 369 GLY A 420 LEU A 468 ASP A 479	ANP A 615 (-4.4A) ANP A 615 (-4.5A) ANP A 615 (-3.3A) ANP A 615 (-3.1A) ANP A 615 ( 3.9A) ANP A 615 (-4.7A) MG A 614 ( 3.2A)	0.87A	4hjoA-2ozoA: 31.3	4hjoA-2ozoA: 20.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2phk	PHOSPHORYLASE KINASE (Oryctolagus cuniculus)	PF00069 (Pkinase)	7	LEU A 25 VAL A 33 ALA A 46 MET A 106 GLY A 109 LEU A 156 THR A 166	ATP A 381 ( 4.3A) ATP A 381 (-4.1A) ATP A 381 (-3.5A) None None ATP A 381 ( 4.8A) ATP A 381 ( 4.6A)	0.49A	4hjoA-2phkA: 23.0	4hjoA-2phkA: 25.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qkw	PROTEIN KINASE (Solanum pimpinellifolium)	PF07714 (Pkinase_Tyr)	6	VAL B 55 ALA B 67 MET B 117 GLY B 120 LEU B 171 THR B 181	None	0.33A	4hjoA-2qkwB: 23.0	4hjoA-2qkwB: 26.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 204 ALA A 215 LYS A 217 THR A 265 GLY A 271 LEU A 328 ASP A 339	ADE A 488 ( 4.9A) ADE A 488 (-3.2A) None ADE A 488 (-4.3A) ADE A 488 ( 4.1A) ADE A 488 (-4.4A) None	0.65A	4hjoA-2qluA: 24.9	4hjoA-2qluA: 26.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2qob	EPHRIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 635 ALA A 651 THR A 699 MET A 702 GLY A 705 LEU A 753	BME A 1 (-4.9A) PTR A 701 ( 4.7A) None PTR A 701 ( 3.5A) None None	0.44A	4hjoA-2qobA: 30.1	4hjoA-2qobA: 33.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r2p	EPHRIN TYPE-A RECEPTOR 5 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	VAL A 689 ALA A 705 THR A 753 MET A 756 GLY A 759 LEU A 807	None	0.45A	4hjoA-2r2pA: 30.4	4hjoA-2r2pA: 33.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	LEU A 724 VAL A 732 ALA A 749 LYS A 751 THR A 796 MET A 799 GLY A 802 LEU A 850 THR A 860 ASP A 861	GW7 A 1 ( 4.2A) GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 (-3.9A) GW7 A 1 (-4.0A) None GW7 A 1 (-3.6A) GW7 A 1 (-4.2A) GW7 A 1 (-3.5A) GW7 A 1 (-4.1A)	0.49A	4hjoA-2r4bA: 39.1	4hjoA-2r4bA: 76.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LYS A 751 MET A 799 GLY A 802 CYH A 803 LEU A 850 THR A 860 ASP A 861	GW7 A 1 (-3.9A) None GW7 A 1 (-3.6A) GW7 A 1 (-2.3A) GW7 A 1 (-4.2A) GW7 A 1 (-3.5A) GW7 A 1 (-4.1A)	0.84A	4hjoA-2r4bA: 39.1	4hjoA-2r4bA: 76.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 226 VAL A 234 ALA A 247 LYS A 249 MET A 304 GLY A 307 LEU A 354 THR A 367	XK9 A1511 (-3.8A) XK9 A1511 (-4.8A) XK9 A1511 ( 4.1A) XK9 A1511 (-4.2A) None XK9 A1511 ( 3.7A) XK9 A1511 (-4.6A) XK9 A1511 (-3.7A)	0.81A	4hjoA-2xk9A: 21.3	4hjoA-2xk9A: 26.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 635 ALA A 651 LYS A 653 THR A 699 MET A 702 GLY A 705 LEU A 753	Q9G A1898 ( 4.7A) Q9G A1898 (-3.2A) Q9G A1898 (-4.8A) Q9G A1898 (-3.5A) None Q9G A1898 ( 3.8A) Q9G A1898 (-4.3A)	0.63A	4hjoA-2xyuA: 30.9	4hjoA-2xyuA: 35.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 68 VAL A 76 ALA A 92 LYS A 94 GLY A 147 LEU A 194 THR A 204	STU A 1 (-3.8A) None STU A 1 (-3.3A) STU A 1 (-2.8A) STU A 1 ( 3.9A) STU A 1 (-4.6A) STU A 1 (-3.6A)	0.77A	4hjoA-2z7rA: 22.4	4hjoA-2z7rA: 26.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 68 VAL A 76 ALA A 92 LYS A 94 GLY A 147 THR A 204 ASP A 205	STU A 1 (-3.8A) None STU A 1 (-3.3A) STU A 1 (-2.8A) STU A 1 ( 3.9A) STU A 1 (-3.6A) STU A 1 ( 3.8A)	0.93A	4hjoA-2z7rA: 22.4	4hjoA-2z7rA: 26.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	8	LEU A 253 VAL A 261 ALA A 273 LYS A 275 THR A 319 MET A 322 GLY A 325 LEU A 374	None	0.72A	4hjoA-2zv7A: 30.1	4hjoA-2zv7A: 32.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 220 LYS A 222 THR A 266 MET A 269 GLY A 272 LEU A 321 ASP A 332	None	0.92A	4hjoA-3d7uA: 31.4	4hjoA-3d7uA: 34.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 209 ALA A 220 THR A 266 MET A 269 GLY A 272 LEU A 321 ASP A 332	None	0.66A	4hjoA-3d7uA: 31.4	4hjoA-3d7uA: 34.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3fzp	PROTEIN TYROSINE KINASE 2 BETA (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 431 VAL A 439 ALA A 455 LYS A 457 GLY A 508 LEU A 556 ASP A 567	AGS A 999 ( 4.4A) AGS A 999 (-4.6A) AGS A 999 (-3.6A) AGS A 999 (-2.5A) None AGS A 999 (-4.5A) AGS A 999 ( 3.9A)	0.87A	4hjoA-3fzpA: 31.0	4hjoA-3fzpA: 34.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3i6u	SERINE/THREONINE-PRO TEIN KINASE CHK2 (Homo sapiens)	PF00069 (Pkinase) PF00498 (FHA)	7	LEU A 226 VAL A 234 ALA A 247 MET A 304 LEU A 354 THR A 367 ASP A 368	None	0.80A	4hjoA-3i6uA: 22.8	4hjoA-3i6uA: 21.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kex	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 696 VAL A 704 LYS A 723 THR A 768 GLY A 774 LEU A 822 ASP A 833	ANP A 1 (-4.4A) ANP A 1 (-3.9A) ANP A 1 (-3.4A) ANP A 1 ( 4.8A) ANP A 1 ( 4.9A) ANP A 1 (-4.7A) MG A1001 ( 3.1A)	0.53A	4hjoA-3kexA: 36.0	4hjoA-3kexA: 53.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	ALA A 665 LYS A 667 THR A 713 MET A 716 GLY A 719 LEU A 767 ASP A 778	None None None None GOL A 403 (-3.4A) None None	0.96A	4hjoA-3kulA: 31.3	4hjoA-3kulA: 33.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 649 ALA A 665 THR A 713 MET A 716 GLY A 719 LEU A 767 ASP A 778	None None None None GOL A 403 (-3.4A) None None	0.62A	4hjoA-3kulA: 31.3	4hjoA-3kulA: 33.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	ALA A 719 THR A 766 MET A 769 GLY A 772 CYH A 773 LEU A 820 THR A 830 ASP A 831	ITI A 1 (-2.9A) ITI A 1 (-3.8A) ITI A 1 (-4.8A) ITI A 1 (-3.5A) ITI A 1 (-4.8A) ITI A 1 (-4.6A) ITI A 1 (-3.8A) ITI A 1 ( 4.6A)	0.95A	4hjoA-3lzbA: 38.7	4hjoA-3lzbA: 88.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 702 ALA A 719 THR A 766 MET A 769 CYH A 773 LEU A 820 THR A 830 ASP A 831	ITI A 1 (-4.8A) ITI A 1 (-2.9A) ITI A 1 (-3.8A) ITI A 1 (-4.8A) ITI A 1 (-4.8A) ITI A 1 (-4.6A) ITI A 1 (-3.8A) ITI A 1 ( 4.6A)	1.03A	4hjoA-3lzbA: 38.7	4hjoA-3lzbA: 88.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 88 VAL A 96 ALA A 109 LYS A 111 GLY A 165 LEU A 212 THR A 222	JOZ A 361 (-4.1A) JOZ A 361 ( 4.7A) JOZ A 361 (-3.4A) SO4 A 5 (-2.8A) None None JOZ A 361 (-3.7A)	0.83A	4hjoA-3nuuA: 22.8	4hjoA-3nuuA: 27.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	6	LEU A 192 VAL A 200 ALA A 213 MET A 266 GLY A 269 LEU A 318	AMP A 577 ( 4.3A) AMP A 577 (-4.3A) AMP A 577 (-3.4A) None None AMP A 577 (-4.8A)	0.49A	4hjoA-3nyoA: 18.2	4hjoA-3nyoA: 19.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	LEU A 726 VAL A 734 ALA A 751 LYS A 753 THR A 798 MET A 801 GLY A 804 LEU A 852 THR A 862 ASP A 863	03Q A 1 (-3.8A) 03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.7A) 03Q A 1 (-4.1A) None 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A) 03Q A 1 (-3.3A) 03Q A 1 (-4.0A)	0.75A	4hjoA-3pp0A: 36.1	4hjoA-3pp0A: 76.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	LEU A 726 VAL A 734 ALA A 751 THR A 798 MET A 801 GLY A 804 CYH A 805 LEU A 852 THR A 862 ASP A 863	03Q A 1 (-3.8A) 03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.1A) None 03Q A 1 ( 3.9A) None 03Q A 1 (-4.4A) 03Q A 1 (-3.3A) 03Q A 1 (-4.0A)	0.62A	4hjoA-3pp0A: 36.1	4hjoA-3pp0A: 76.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q4t	ACTIVIN RECEPTOR TYPE-2A (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 206 ALA A 217 THR A 267 GLY A 273 LEU A 329 ASP A 340	TAK A 2 ( 4.9A) TAK A 2 (-3.5A) TAK A 2 (-3.5A) TAK A 2 (-3.6A) TAK A 2 (-4.6A) None	0.57A	4hjoA-3q4tA: 24.5	4hjoA-3q4tA: 25.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3she	MAP KINASE-ACTIVATED PROTEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 50 VAL A 58 ALA A 71 LYS A 73 MET A 121 LEU A 173 THR A 186	I85 A 350 (-3.7A) I85 A 350 (-4.9A) I85 A 350 (-3.3A) I85 A 350 (-2.8A) None None I85 A 350 ( 4.0A)	0.98A	4hjoA-3sheA: 13.7	4hjoA-3sheA: 23.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3she	MAP KINASE-ACTIVATED PROTEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 50 VAL A 58 LYS A 73 MET A 121 LEU A 173 THR A 186 ASP A 187	I85 A 350 (-3.7A) I85 A 350 (-4.9A) I85 A 350 (-2.8A) None None I85 A 350 ( 4.0A) I85 A 350 (-3.3A)	1.08A	4hjoA-3sheA: 13.7	4hjoA-3sheA: 23.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 423 VAL A 431 ALA A 443 LYS A 445 THR A 489 GLY A 495 CYH A 496 LEU A 543	PP2 A 1 (-4.1A) PP2 A 1 (-4.5A) PP2 A 1 (-3.2A) PP2 A 1 (-4.5A) PP2 A 1 (-3.3A) PP2 A 1 ( 4.2A) None PP2 A 1 (-4.6A)	0.54A	4hjoA-3sxsA: 30.7	4hjoA-3sxsA: 30.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ulz	BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	8	LEU A 295 VAL A 303 ALA A 315 LYS A 317 MET A 366 GLY A 369 LEU A 423 ASP A 434	None	0.82A	4hjoA-3ulzA: 17.7	4hjoA-3ulzA: 26.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 544 VAL A 552 ALA A 570 MET A 620 GLY A 623 LEU A 686	0F4 A 902 ( 4.2A) None 0F4 A 902 (-3.2A) None 0F4 A 902 (-3.4A) 0F4 A 902 (-4.5A)	0.46A	4hjoA-3v5qA: 24.1	4hjoA-3v5qA: 29.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 75 VAL A 83 ALA A 96 LYS A 98 MET A 147 GLY A 150 LEU A 198 ASP A 209	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) None ANP A 401 ( 4.3A) ANP A 401 (-4.8A) MG A 402 (-3.2A)	0.61A	4hjoA-3wigA: 10.2	4hjoA-3wigA: 26.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A1951 VAL A1959 ALA A1978 MET A2029 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.51A	4hjoA-3zbfA: 29.7	4hjoA-3zbfA: 35.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zfx	EPHRIN TYPE-B RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 649 LYS A 651 THR A 697 MET A 700 GLY A 703 LEU A 751 ASP A 762	None	0.87A	4hjoA-3zfxA: 32.0	4hjoA-3zfxA: 36.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zfx	EPHRIN TYPE-B RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 633 ALA A 649 LYS A 651 THR A 697 MET A 700 GLY A 703 LEU A 751	None	0.73A	4hjoA-3zfxA: 32.0	4hjoA-3zfxA: 36.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4af3	AURORA KINASE B (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 83 VAL A 91 ALA A 104 LYS A 106 GLY A 160 LEU A 207	VX6 A 500 (-3.8A) VX6 A 500 ( 4.8A) VX6 A 500 (-3.4A) VX6 A 500 (-3.3A) VX6 A 500 (-3.3A) VX6 A 500 (-4.6A)	0.48A	4hjoA-4af3A: 20.0	4hjoA-4af3A: 25.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4at3	BDNF/NT-3 GROWTH FACTORS RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 560 VAL A 568 ALA A 586 MET A 636 GLY A 639 LEU A 699	LTI A1839 ( 4.2A) None LTI A1839 (-3.3A) None LTI A1839 (-3.4A) LTI A1839 (-4.2A)	0.53A	4hjoA-4at3A: 10.1	4hjoA-4at3A: 30.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4aw5	EPHRIN TYPE-B RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 105 ALA A 121 LYS A 123 THR A 169 MET A 172 GLY A 175 LEU A 223	30K A1365 ( 4.6A) 30K A1365 (-3.2A) 30K A1365 (-3.8A) 30K A1365 (-3.8A) None 30K A1365 (-3.5A) 30K A1365 (-4.5A)	0.54A	4hjoA-4aw5A: 30.7	4hjoA-4aw5A: 32.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	7	VAL A 222 ALA A 233 LYS A 235 THR A 283 GLY A 289 LEU A 343 ASP A 354	TAK A1507 (-4.7A) TAK A1507 (-3.3A) TAK A1507 ( 4.5A) TAK A1507 (-3.6A) TAK A1507 (-3.5A) TAK A1507 (-4.7A) TAK A1507 (-3.5A)	0.69A	4hjoA-4c02A: 25.2	4hjoA-4c02A: 24.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c0t	LIKELY PROTEIN KINASE (Candida albicans)	PF00069 (Pkinase)	7	LEU A 246 VAL A 254 ALA A 267 GLY A 324 LEU A 371 THR A 381 ASP A 382	None	0.88A	4hjoA-4c0tA: 21.5	4hjoA-4c0tA: 16.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f0i	HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 515 VAL A 523 ALA A 541 MET A 591 GLY A 594 LEU A 656	None	0.43A	4hjoA-4f0iA: 29.5	4hjoA-4f0iA: 31.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fl3	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	7	LEU A 377 VAL A 385 ALA A 400 LYS A 402 GLY A 454 LEU A 501 ASP A 512	ANP A 701 ( 4.6A) ANP A 701 (-4.1A) ANP A 701 (-3.3A) ANP A 701 (-2.7A) ANP A 701 ( 4.2A) ANP A 701 (-4.5A) MG A 702 ( 3.1A)	0.56A	4hjoA-4fl3A: 32.8	4hjoA-4fl3A: 21.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A1122 VAL A1130 ALA A1148 MET A1199 GLY A1202 LEU A1256	0UV A1501 (-3.8A) 0UV A1501 (-4.5A) 0UV A1501 (-3.4A) None 0UV A1501 (-3.6A) 0UV A1501 (-4.6A)	0.49A	4hjoA-4fodA: 29.6	4hjoA-4fodA: 31.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	LEU A 156 VAL A 164 ALA A 177 LYS A 179 GLY A 233 THR A 291 ASP A 292	0XZ A 501 ( 4.1A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 503 ( 2.8A) None 0XZ A 501 ( 4.1A) 0XZ A 501 ( 3.4A)	0.97A	4hjoA-4gv1A: 21.2	4hjoA-4gv1A: 23.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	8	LEU A 132 VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 211 LEU A 259 ASP A 270	None	0.70A	4hjoA-4hzsA: 32.4	4hjoA-4hzsA: 35.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 132 VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 211 LEU A 259	1G0 A 401 ( 4.5A) 1G0 A 401 (-4.4A) 1G0 A 401 (-3.6A) 1G0 A 401 (-3.7A) 1G0 A 401 (-3.2A) 1G0 A 401 ( 4.5A) 1G0 A 401 (-4.6A)	0.81A	4hjoA-4id7A: 31.5	4hjoA-4id7A: 35.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	LEU A 273 VAL A 281 ALA A 293 LYS A 295 MET A 341 GLY A 344 LEU A 393 ASP A 404	0J9 A 601 (-4.0A) 0J9 A 601 (-4.4A) 0J9 A 601 (-3.3A) 0J9 A 601 ( 4.7A) None 0J9 A 601 ( 4.1A) 0J9 A 601 (-4.5A) 0J9 A 601 (-3.1A)	0.55A	4hjoA-4k11A: 29.3	4hjoA-4k11A: 26.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	8	LEU A 273 VAL A 281 ALA A 293 LYS A 295 MET A 341 GLY A 344 LEU A 393 ASP A 404	VGG A 601 (-3.2A) VGG A 601 ( 3.5A) VGG A 601 (-3.5A) VGG A 601 (-3.8A) None VGG A 601 ( 3.2A) VGG A 601 (-4.5A) VGG A 601 ( 4.7A)	0.99A	4hjoA-4lggA: 29.0	4hjoA-4lggA: 32.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	8	VAL A 36 ALA A 49 LYS A 51 THR A 95 MET A 98 GLY A 101 LEU A 150 ASP A 161	ANP A 401 (-4.5A) ANP A 401 (-3.1A) ANP A 401 (-2.9A) ANP A 401 (-3.8A) None None ANP A 401 (-4.8A) MG A 403 ( 3.1A)	0.60A	4hjoA-4m69A: 26.0	4hjoA-4m69A: 25.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 46 VAL A 54 ALA A 67 LYS A 69 THR A 123 GLY A 128 LEU A 180	SIN A 401 ( 3.9A) None SIN A 401 ( 3.7A) None None SIN A 401 (-3.5A) SIN A 401 ( 4.5A)	0.65A	4hjoA-4o38A: 19.3	4hjoA-4o38A: 21.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oli	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 595 VAL A 603 LYS A 642 THR A 687 GLY A 693 LEU A 741	2TT A1201 (-4.1A) 2TT A1201 (-4.2A) 2TT A1201 ( 4.6A) None 2TT A1201 (-3.5A) 2TT A1201 (-4.1A)	0.52A	4hjoA-4oliA: 28.7	4hjoA-4oliA: 20.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2k	EPHRIN TYPE-A RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	VAL A 627 ALA A 644 THR A 692 MET A 695 GLY A 698 LEU A 746	None	0.47A	4hjoA-4p2kA: 30.4	4hjoA-4p2kA: 34.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	8	LEU A 14 VAL A 22 ALA A 35 LYS A 37 THR A 81 MET A 84 GLY A 87 LEU A 136	ACP A1264 ( 4.5A) ACP A1264 (-4.7A) ACP A1264 (-2.9A) None ACP A1264 (-4.5A) None ACP A1264 (-3.5A) ACP A1264 ( 4.8A)	0.64A	4hjoA-4ueuA: 29.7	4hjoA-4ueuA: 35.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4uy9	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 158 ALA A 169 LYS A 171 GLY A 226 LEU A 275 THR A 293 ASP A 294	None	1.26A	4hjoA-4uy9A: 27.5	4hjoA-4uy9A: 31.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wbo	RHODOPSIN KINASE (Bos taurus)	PF00069 (Pkinase) PF00615 (RGS)	7	LEU A 193 VAL A 201 ALA A 214 LYS A 216 MET A 267 GLY A 270 LEU A 321	ANW A 601 ( 4.0A) None ANW A 601 (-3.4A) None None ANW A 601 ( 4.5A) ANW A 601 (-4.9A)	0.76A	4hjoA-4wboA: 21.9	4hjoA-4wboA: 20.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	8	LEU B 267 VAL B 275 ALA B 288 LYS B 290 THR B 334 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 (-3.3A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.42A	4hjoA-4xeyB: 30.3	4hjoA-4xeyB: 28.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	9	LEU A 408 VAL A 416 ALA A 428 THR A 474 MET A 477 GLY A 480 CYH A 481 LEU A 528 ASP A 539	None	0.96A	4hjoA-4xi2A: 31.8	4hjoA-4xi2A: 23.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	8	LEU A 408 VAL A 416 ALA A 428 LYS A 430 MET A 477 GLY A 480 LEU A 528 ASP A 539	746 A 702 (-3.8A) 746 A 702 ( 4.3A) 746 A 702 (-2.4A) 746 A 702 (-3.7A) None 746 A 702 (-3.6A) 746 A 702 (-4.4A) 746 A 702 (-3.7A)	0.89A	4hjoA-4y93A: 32.4	4hjoA-4y93A: 24.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	9	LEU A 408 VAL A 416 ALA A 428 THR A 474 MET A 477 GLY A 480 CYH A 481 LEU A 528 ASP A 539	746 A 702 (-3.8A) 746 A 702 ( 4.3A) 746 A 702 (-2.4A) 746 A 702 (-3.7A) None 746 A 702 (-3.6A) None 746 A 702 (-4.4A) 746 A 702 (-3.7A)	0.74A	4hjoA-4y93A: 32.4	4hjoA-4y93A: 24.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ysj	CALMODULIN-LIKE DOMAIN PROTEIN KINASE (Eimeria tenella)	PF00069 (Pkinase) PF13499 (EF-hand_7)	7	LEU A 34 VAL A 42 ALA A 55 LYS A 57 THR A 105 GLY A 111 LEU A 158	ADP A 506 ( 3.8A) ADP A 506 (-4.3A) ADP A 506 (-3.3A) ADP A 506 (-2.4A) ADP A 506 ( 4.6A) None ADP A 506 (-4.7A)	1.03A	4hjoA-4ysjA: 19.3	4hjoA-4ysjA: 22.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 484 VAL A 492 ALA A 512 LYS A 514 GLY A 567 LEU A 630 ASP A 641	38O A1769 (-3.2A) 38O A1769 (-4.5A) 38O A1769 (-3.6A) 38O A1769 ( 3.1A) 38O A1769 (-3.4A) 38O A1769 (-4.6A) 38O A1769 (-4.0A)	0.89A	4hjoA-5a46A: 29.4	4hjoA-5a46A: 32.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 599 VAL A 607 ALA A 625 LYS A 627 THR A 674 GLY A 680 LEU A 825	748 A1001 (-3.8A) 748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 (-4.0A) 748 A1001 (-3.2A) 748 A1001 ( 4.0A) 748 A1001 (-4.3A)	0.64A	4hjoA-5grnA: 29.3	4hjoA-5grnA: 31.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 718 ALA A 743 MET A 793 GLY A 796 CYH A 797 LEU A 844 THR A 854 ASP A 855	6HJ A1101 ( 4.6A) 6HJ A1101 (-3.1A) None 6HJ A1101 ( 4.5A) 6HJ A1101 (-1.6A) 6HJ A1101 ( 4.8A) 6HJ A1101 (-3.9A) 6HJ A1101 (-4.3A)	0.90A	4hjoA-5j9zA: 35.2	4hjoA-5j9zA: 99.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 718 VAL A 726 ALA A 743 LYS A 745 MET A 793 GLY A 796 LEU A 844	6HJ A1101 ( 4.6A) 6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) 6HJ A1101 (-4.2A) None 6HJ A1101 ( 4.5A) 6HJ A1101 ( 4.8A)	0.67A	4hjoA-5j9zA: 35.2	4hjoA-5j9zA: 99.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 718 VAL A 726 ALA A 743 MET A 793 GLY A 796 CYH A 797 LEU A 844 THR A 854	6HJ A1101 ( 4.6A) 6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) None 6HJ A1101 ( 4.5A) 6HJ A1101 (-1.6A) 6HJ A1101 ( 4.8A) 6HJ A1101 (-3.9A)	0.82A	4hjoA-5j9zA: 35.2	4hjoA-5j9zA: 99.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5kbr	SERINE/THREONINE-PRO TEIN KINASE PAK 1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 284 ALA A 297 LYS A 299 GLY A 350 LEU A 396 THR A 406	IPW A 601 (-4.2A) IPW A 601 (-3.5A) IPW A 601 (-4.5A) IPW A 601 ( 3.8A) IPW A 601 (-4.5A) IPW A 601 (-3.7A)	0.55A	4hjoA-5kbrA: 22.4	4hjoA-5kbrA: 26.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpy	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	7	VAL A 897 ALA A 909 LYS A 911 MET A 959 GLY A 962 LEU A1016 ASP A1027	ATP A1200 ( 4.5A) ATP A1200 (-3.5A) ATP A1200 (-3.8A) None ATP A1200 ( 4.0A) ATP A1200 (-4.6A) ATP A1200 (-4.1A)	0.85A	4hjoA-5lpyA: 23.4	4hjoA-5lpyA: 27.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vil	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 5 (Homo sapiens)	no annotation	7	LEU A 686 VAL A 694 ALA A 707 LYS A 709 GLY A 760 LEU A 810 ASP A 822	9E1 A1001 (-3.7A) 9E1 A1001 ( 4.0A) 9E1 A1001 (-3.5A) 9E1 A1001 (-2.8A) 9E1 A1001 (-3.4A) 9E1 A1001 (-4.5A) 9E1 A1001 (-3.6A)	1.08A	4hjoA-5vilA: 15.9	4hjoA-5vilA: 11.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	no annotation	8	LEU A 24 VAL A 32 ALA A 45 LYS A 47 THR A 95 MET A 98 GLY A 101 LEU A 153	9WS A 401 ( 4.2A) 9WS A 401 ( 4.6A) 9WS A 401 (-3.3A) 9WS A 401 (-3.3A) 9WS A 401 (-3.2A) None 9WS A 401 ( 4.3A) 9WS A 401 (-4.6A)	0.58A	4hjoA-5w5jA: 23.8	4hjoA-5w5jA: 27.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	9	LEU A 891 VAL A 899 ALA A 917 LYS A 919 THR A 963 GLY A 969 LEU A1017 THR A1027 ASP A1028	ANP A1201 (-4.1A) ANP A1201 (-4.4A) ANP A1201 (-3.3A) ANP A1201 (-3.8A) ANP A1201 (-3.9A) ANP A1201 ( 4.6A) ANP A1201 (-4.7A) ANP A1201 ( 4.9A) MG A1202 ( 3.0A)	0.61A	4hjoA-5wnoA: 34.4	4hjoA-5wnoA: 12.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	7	LEU A 33 VAL A 41 ALA A 54 LYS A 56 GLY A 105 LEU A 153 ASP A 164	ANP A 501 ( 3.8A) ANP A 501 (-4.4A) ANP A 501 ( 3.7A) ANP A 501 (-2.4A) ANP A 501 ( 4.0A) ANP A 501 (-4.6A) MG A 502 ( 3.1A)	0.57A	4hjoA-6ao5A: 24.5	4hjoA-6ao5A: 27.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cz4	PROTEIN-TYROSINE KINASE 6 (Homo sapiens)	no annotation	8	LEU A 197 VAL A 205 ALA A 217 LYS A 219 THR A 264 MET A 267 GLY A 270 LEU A 319	FKY A9001 (-4.1A) FKY A9001 ( 4.6A) FKY A9001 (-3.3A) None FKY A9001 (-3.0A) None FKY A9001 (-3.3A) FKY A9001 ( 4.9A)	0.84A	4hjoA-6cz4A: 31.8	4hjoA-6cz4A: 16.38

[["4HJO_A_AQ4A1001_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",7,"ALA A 428;LYS A 430;THR A 474;MET A 477;GLY A 480;LEU A 528;ASP A 539","None","0.96A","4hjoA-1k2pA:30.0","4hjoA-1k2pA:32.31"],["4HJO_A_AQ4A1001_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",7,"ALA A 428;THR A 474;MET A 477;GLY A 480;CYH A 481;LEU A 528;ASP A 539","None","0.68A","4hjoA-1k2pA:30.0","4hjoA-1k2pA:32.31"],["4HJO_A_AQ4A1001_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",7,"LEU A 408;VAL A 416;LYS A 430;MET A 477;GLY A 480;LEU A 528;ASP A 539","None","1.10A","4hjoA-1k2pA:30.0","4hjoA-1k2pA:32.31"],["4HJO_A_AQ4A1001_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",7,"LEU A 408;VAL A 416;MET A 477;GLY A 480;CYH A 481;LEU A 528;ASP A 539","None","0.97A","4hjoA-1k2pA:30.0","4hjoA-1k2pA:32.31"],["4HJO_A_AQ4A1001_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",7,"VAL A 416;ALA A 428;LYS A 430;MET A 477;GLY A 480;LEU A 528;ASP A 539","None","0.99A","4hjoA-1k2pA:30.0","4hjoA-1k2pA:32.31"],["4HJO_A_AQ4A1001_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",7,"VAL A 416;ALA A 428;MET A 477;GLY A 480;CYH A 481;LEU A 528;ASP A 539","None","0.87A","4hjoA-1k2pA:30.0","4hjoA-1k2pA:32.31"],["4HJO_A_AQ4A1001_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"ALA A 220;LYS A 222;THR A 266;MET A 269;GLY A 272;LEU A 321;ASP A 332","None","0.92A","4hjoA-1k9aA:30.5","4hjoA-1k9aA:26.17"],["4HJO_A_AQ4A1001_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"VAL A 209;ALA A 220;THR A 266;MET A 269;GLY A 272;LEU A 321;ASP A 332","None","0.66A","4hjoA-1k9aA:30.5","4hjoA-1k9aA:26.17"],["4HJO_A_AQ4A1001_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;THR A 334;MET A 337;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-3.7A);None;P16 A   2 (-4.4A)","0.67A","4hjoA-1opkA:29.7","4hjoA-1opkA:25.00"],["4HJO_A_AQ4A1001_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 267;VAL A 275;ALA A 288;THR A 334;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-3.7A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.63A","4hjoA-1opkA:29.7","4hjoA-1opkA:25.00"],["4HJO_A_AQ4A1001_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",8,"LEU A  78;VAL A  86;ALA A  99;LYS A 101;MET A 150;GLY A 153;LEU A 201;ASP A 212","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);None;ATP A 535 ( 4.7A);ATP A 535 (-4.8A); MG A 536 (-3.3A)","0.52A","4hjoA-1s9iA:9.1","4hjoA-1s9iA:26.01"],["4HJO_A_AQ4A1001_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",7,"VAL A 377;ALA A 389;LYS A 391;GLY A 441;CYH A 442;LEU A 489;ASP A 500","None","0.81A","4hjoA-1snxA:31.4","4hjoA-1snxA:31.74"],["4HJO_A_AQ4A1001_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",7,"VAL A 377;ALA A 389;LYS A 391;MET A 438;GLY A 441;CYH A 442;LEU A 489","None","0.71A","4hjoA-1snxA:31.4","4hjoA-1snxA:31.74"],["4HJO_A_AQ4A1001_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",7,"LEU A 595;VAL A 603;ALA A 621;LYS A 623;THR A 670;GLY A 676;LEU A 799","STI A   3 ( 3.8A);STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 (-3.7A);STI A   3 (-3.2A);STI A   3 ( 3.8A);STI A   3 (-4.4A)","0.68A","4hjoA-1t46A:25.4","4hjoA-1t46A:31.68"],["4HJO_A_AQ4A1001_1","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",7,"LEU A  15;VAL A  23;ALA A  36;LYS A  38;GLY A  90;LEU A 137;ASP A 148","HYM A 400 (-4.2A);HYM A 400 (-4.3A);HYM A 400 (-3.5A);HYM A 400 (-3.2A);None;HYM A 400 (-4.5A);HYM A 400 (-3.9A)","0.91A","4hjoA-1zltA:20.9","4hjoA-1zltA:24.86"],["4HJO_A_AQ4A1001_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",7,"LEU X  17;VAL X  25;ALA X  37;LYS X  39;MET X  85;LEU X 137;ASP X 148","STU X 902 (-3.8A);STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 (-3.1A);None;STU X 902 (-4.4A);STU X 902 (-3.6A)","0.96A","4hjoA-2dq7X:30.9","4hjoA-2dq7X:32.85"],["4HJO_A_AQ4A1001_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",7,"LEU X  17;VAL X  25;ALA X  37;LYS X  39;THR X  82;MET X  85;LEU X 137","STU X 902 (-3.8A);STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 (-3.1A);STU X 902 (-4.1A);None;STU X 902 (-4.4A)","0.77A","4hjoA-2dq7X:30.9","4hjoA-2dq7X:32.85"],["4HJO_A_AQ4A1001_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",7,"LEU X  17;VAL X  25;ALA X  37;MET X  85;GLY X  88;LEU X 137;ASP X 148","STU X 902 (-3.8A);STU X 902 ( 4.8A);STU X 902 (-3.1A);None;STU X 902 (-3.5A);STU X 902 (-4.4A);STU X 902 (-3.6A)","0.65A","4hjoA-2dq7X:30.9","4hjoA-2dq7X:32.85"],["4HJO_A_AQ4A1001_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",7,"LEU X  17;VAL X  25;ALA X  37;THR X  82;MET X  85;GLY X  88;LEU X 137","STU X 902 (-3.8A);STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 (-4.1A);None;STU X 902 (-3.5A);STU X 902 (-4.4A)","0.53A","4hjoA-2dq7X:30.9","4hjoA-2dq7X:32.85"],["4HJO_A_AQ4A1001_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",9,"LEU A 273;VAL A 281;ALA A 293;LYS A 295;THR A 338;MET A 341;GLY A 344;LEU A 393;ASP A 404","H8H A 534 (-3.8A);H8H A 534 (-4.4A);H8H A 534 (-3.2A);H8H A 534 (-3.7A);H8H A 534 (-3.1A);None;H8H A 534 (-3.3A);H8H A 534 (-4.5A);H8H A 534 (-4.2A)","0.47A","4hjoA-2h8hA:35.5","4hjoA-2h8hA:22.59"],["4HJO_A_AQ4A1001_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",9,"LEU A 273;VAL A 281;ALA A 293;LYS A 295;THR A 338;MET A 341;GLY A 344;LEU A 393;ASP A 404","QUE A   1 (-3.9A);QUE A   1 ( 4.8A);QUE A   1 (-3.5A);None;QUE A   1 (-3.3A);None;QUE A   1 (-3.0A);QUE A   1 (-4.4A);None","0.60A","4hjoA-2hckA:32.7","4hjoA-2hckA:26.27"],["4HJO_A_AQ4A1001_1","2hen","Mus musculus","EPHRIN TYPE-B RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 643;ALA A 659;LYS A 661;THR A 707;MET A 710;GLY A 713;LEU A 761","ADP A 400 ( 4.4A);ADP A 400 (-3.2A);ADP A 400 (-2.7A);ADP A 400 (-4.7A);None;ADP A 400 ( 4.2A);ADP A 400 ( 4.7A)","0.74A","4hjoA-2henA:30.1","4hjoA-2henA:33.33"],["4HJO_A_AQ4A1001_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",7,"LEU A 251;VAL A 259;ALA A 271;THR A 316;MET A 319;GLY A 322;LEU A 371","1BM A 499 ( 3.7A);1BM A 499 ( 4.8A);1BM A 499 (-3.6A);1BM A 499 (-3.2A);None;1BM A 499 (-3.5A);1BM A 499 (-4.4A)","0.35A","4hjoA-2hk5A:29.9","4hjoA-2hk5A:33.33"],["4HJO_A_AQ4A1001_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",8,"LEU A 248;VAL A 256;ALA A 269;LYS A 271;THR A 315;MET A 318;GLY A 321;LEU A 370","GIN A 600 ( 4.6A);GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-3.4A);None;None;GIN A 600 (-4.7A)","0.69A","4hjoA-2hz0A:30.1","4hjoA-2hz0A:35.67"],["4HJO_A_AQ4A1001_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",7,"LEU A 251;ALA A 271;LYS A 273;THR A 316;MET A 319;GLY A 322;LEU A 371","None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.4A);1N8 A 501 ( 3.3A);1N8 A 501 ( 4.4A);1N8 A 501 ( 3.5A);1N8 A 501 ( 4.3A)","0.78A","4hjoA-2og8A:29.1","4hjoA-2og8A:33.33"],["4HJO_A_AQ4A1001_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",7,"LEU A 251;VAL A 259;ALA A 271;LYS A 273;THR A 316;MET A 319;GLY A 322","None;None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.4A);1N8 A 501 ( 3.3A);1N8 A 501 ( 4.4A);1N8 A 501 ( 3.5A)","0.80A","4hjoA-2og8A:29.1","4hjoA-2og8A:33.33"],["4HJO_A_AQ4A1001_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",7,"LEU A 344;VAL A 352;ALA A 367;LYS A 369;GLY A 418;LEU A 468;ASP A 479","ANP A 615 (-4.4A);ANP A 615 (-4.5A);ANP A 615 (-3.3A);ANP A 615 (-3.1A);ANP A 615 ( 4.0A);ANP A 615 (-4.7A); MG A 614 ( 3.2A)","1.13A","4hjoA-2ozoA:31.3","4hjoA-2ozoA:20.78"],["4HJO_A_AQ4A1001_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",7,"LEU A 344;VAL A 352;ALA A 367;LYS A 369;GLY A 420;LEU A 468;ASP A 479","ANP A 615 (-4.4A);ANP A 615 (-4.5A);ANP A 615 (-3.3A);ANP A 615 (-3.1A);ANP A 615 ( 3.9A);ANP A 615 (-4.7A); MG A 614 ( 3.2A)","0.87A","4hjoA-2ozoA:31.3","4hjoA-2ozoA:20.78"],["4HJO_A_AQ4A1001_1","2phk","Oryctolagus cuniculus","PHOSPHORYLASE KINASE","PF00069(Pkinase)",7,"LEU A  25;VAL A  33;ALA A  46;MET A 106;GLY A 109;LEU A 156;THR A 166","ATP A 381 ( 4.3A);ATP A 381 (-4.1A);ATP A 381 (-3.5A);None;None;ATP A 381 ( 4.8A);ATP A 381 ( 4.6A)","0.49A","4hjoA-2phkA:23.0","4hjoA-2phkA:25.84"],["4HJO_A_AQ4A1001_1","2qkw","Solanum pimpinellifolium","PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"VAL B  55;ALA B  67;MET B 117;GLY B 120;LEU B 171;THR B 181","None","0.33A","4hjoA-2qkwB:23.0","4hjoA-2qkwB:26.04"],["4HJO_A_AQ4A1001_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",7,"VAL A 204;ALA A 215;LYS A 217;THR A 265;GLY A 271;LEU A 328;ASP A 339","ADE A 488 ( 4.9A);ADE A 488 (-3.2A);None;ADE A 488 (-4.3A);ADE A 488 ( 4.1A);ADE A 488 (-4.4A);None","0.65A","4hjoA-2qluA:24.9","4hjoA-2qluA:26.04"],["4HJO_A_AQ4A1001_1","2qob","Homo sapiens","EPHRIN RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A 635;ALA A 651;THR A 699;MET A 702;GLY A 705;LEU A 753","BME A   1 (-4.9A);PTR A 701 ( 4.7A);None;PTR A 701 ( 3.5A);None;None","0.44A","4hjoA-2qobA:30.1","4hjoA-2qobA:33.70"],["4HJO_A_AQ4A1001_1","2r2p","Homo sapiens","EPHRIN TYPE-A RECEPTOR 5","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"VAL A 689;ALA A 705;THR A 753;MET A 756;GLY A 759;LEU A 807","None","0.45A","4hjoA-2r2pA:30.4","4hjoA-2r2pA:33.91"],["4HJO_A_AQ4A1001_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",10,"LEU A 724;VAL A 732;ALA A 749;LYS A 751;THR A 796;MET A 799;GLY A 802;LEU A 850;THR A 860;ASP A 861","GW7 A   1 ( 4.2A);GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 (-3.9A);GW7 A   1 (-4.0A);None;GW7 A   1 (-3.6A);GW7 A   1 (-4.2A);GW7 A   1 (-3.5A);GW7 A   1 (-4.1A)","0.49A","4hjoA-2r4bA:39.1","4hjoA-2r4bA:76.23"],["4HJO_A_AQ4A1001_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",7,"LYS A 751;MET A 799;GLY A 802;CYH A 803;LEU A 850;THR A 860;ASP A 861","GW7 A   1 (-3.9A);None;GW7 A   1 (-3.6A);GW7 A   1 (-2.3A);GW7 A   1 (-4.2A);GW7 A   1 (-3.5A);GW7 A   1 (-4.1A)","0.84A","4hjoA-2r4bA:39.1","4hjoA-2r4bA:76.23"],["4HJO_A_AQ4A1001_1","2xk9","Homo sapiens","CHECKPOINT KINASE 2","PF00069(Pkinase)",8,"LEU A 226;VAL A 234;ALA A 247;LYS A 249;MET A 304;GLY A 307;LEU A 354;THR A 367","XK9 A1511 (-3.8A);XK9 A1511 (-4.8A);XK9 A1511 ( 4.1A);XK9 A1511 (-4.2A);None;XK9 A1511 ( 3.7A);XK9 A1511 (-4.6A);XK9 A1511 (-3.7A)","0.81A","4hjoA-2xk9A:21.3","4hjoA-2xk9A:26.98"],["4HJO_A_AQ4A1001_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",7,"VAL A 635;ALA A 651;LYS A 653;THR A 699;MET A 702;GLY A 705;LEU A 753","Q9G A1898 ( 4.7A);Q9G A1898 (-3.2A);Q9G A1898 (-4.8A);Q9G A1898 (-3.5A);None;Q9G A1898 ( 3.8A);Q9G A1898 (-4.3A)","0.63A","4hjoA-2xyuA:30.9","4hjoA-2xyuA:35.78"],["4HJO_A_AQ4A1001_1","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",7,"LEU A  68;VAL A  76;ALA A  92;LYS A  94;GLY A 147;LEU A 194;THR A 204","STU A   1 (-3.8A);None;STU A   1 (-3.3A);STU A   1 (-2.8A);STU A   1 ( 3.9A);STU A   1 (-4.6A);STU A   1 (-3.6A)","0.77A","4hjoA-2z7rA:22.4","4hjoA-2z7rA:26.98"],["4HJO_A_AQ4A1001_1","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",7,"LEU A  68;VAL A  76;ALA A  92;LYS A  94;GLY A 147;THR A 204;ASP A 205","STU A   1 (-3.8A);None;STU A   1 (-3.3A);STU A   1 (-2.8A);STU A   1 ( 3.9A);STU A   1 (-3.6A);STU A   1 ( 3.8A)","0.93A","4hjoA-2z7rA:22.4","4hjoA-2z7rA:26.98"],["4HJO_A_AQ4A1001_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",8,"LEU A 253;VAL A 261;ALA A 273;LYS A 275;THR A 319;MET A 322;GLY A 325;LEU A 374","None","0.72A","4hjoA-2zv7A:30.1","4hjoA-2zv7A:32.84"],["4HJO_A_AQ4A1001_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",7,"ALA A 220;LYS A 222;THR A 266;MET A 269;GLY A 272;LEU A 321;ASP A 332","None","0.92A","4hjoA-3d7uA:31.4","4hjoA-3d7uA:34.53"],["4HJO_A_AQ4A1001_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",7,"VAL A 209;ALA A 220;THR A 266;MET A 269;GLY A 272;LEU A 321;ASP A 332","None","0.66A","4hjoA-3d7uA:31.4","4hjoA-3d7uA:34.53"],["4HJO_A_AQ4A1001_1","3fzp","Homo sapiens","PROTEIN TYROSINE KINASE 2 BETA","PF07714(Pkinase_Tyr)",7,"LEU A 431;VAL A 439;ALA A 455;LYS A 457;GLY A 508;LEU A 556;ASP A 567","AGS A 999 ( 4.4A);AGS A 999 (-4.6A);AGS A 999 (-3.6A);AGS A 999 (-2.5A);None;AGS A 999 (-4.5A);AGS A 999 ( 3.9A)","0.87A","4hjoA-3fzpA:31.0","4hjoA-3fzpA:34.52"],["4HJO_A_AQ4A1001_1","3i6u","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK2","PF00069(Pkinase);PF00498(FHA)",7,"LEU A 226;VAL A 234;ALA A 247;MET A 304;LEU A 354;THR A 367;ASP A 368","None","0.80A","4hjoA-3i6uA:22.8","4hjoA-3i6uA:21.86"],["4HJO_A_AQ4A1001_1","3kex","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","PF07714(Pkinase_Tyr)",7,"LEU A 696;VAL A 704;LYS A 723;THR A 768;GLY A 774;LEU A 822;ASP A 833","ANP A   1 (-4.4A);ANP A   1 (-3.9A);ANP A   1 (-3.4A);ANP A   1 ( 4.8A);ANP A   1 ( 4.9A);ANP A   1 (-4.7A); MG A1001 ( 3.1A)","0.53A","4hjoA-3kexA:36.0","4hjoA-3kexA:53.12"],["4HJO_A_AQ4A1001_1","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"ALA A 665;LYS A 667;THR A 713;MET A 716;GLY A 719;LEU A 767;ASP A 778","None;None;None;None;GOL A 403 (-3.4A);None;None","0.96A","4hjoA-3kulA:31.3","4hjoA-3kulA:33.14"],["4HJO_A_AQ4A1001_1","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 649;ALA A 665;THR A 713;MET A 716;GLY A 719;LEU A 767;ASP A 778","None;None;None;None;GOL A 403 (-3.4A);None;None","0.62A","4hjoA-3kulA:31.3","4hjoA-3kulA:33.14"],["4HJO_A_AQ4A1001_1","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",8,"ALA A 719;THR A 766;MET A 769;GLY A 772;CYH A 773;LEU A 820;THR A 830;ASP A 831","ITI A   1 (-2.9A);ITI A   1 (-3.8A);ITI A   1 (-4.8A);ITI A   1 (-3.5A);ITI A   1 (-4.8A);ITI A   1 (-4.6A);ITI A   1 (-3.8A);ITI A   1 ( 4.6A)","0.95A","4hjoA-3lzbA:38.7","4hjoA-3lzbA:88.07"],["4HJO_A_AQ4A1001_1","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",8,"VAL A 702;ALA A 719;THR A 766;MET A 769;CYH A 773;LEU A 820;THR A 830;ASP A 831","ITI A   1 (-4.8A);ITI A   1 (-2.9A);ITI A   1 (-3.8A);ITI A   1 (-4.8A);ITI A   1 (-4.8A);ITI A   1 (-4.6A);ITI A   1 (-3.8A);ITI A   1 ( 4.6A)","1.03A","4hjoA-3lzbA:38.7","4hjoA-3lzbA:88.07"],["4HJO_A_AQ4A1001_1","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",7,"LEU A  88;VAL A  96;ALA A 109;LYS A 111;GLY A 165;LEU A 212;THR A 222","JOZ A 361 (-4.1A);JOZ A 361 ( 4.7A);JOZ A 361 (-3.4A);SO4 A   5 (-2.8A);None;None;JOZ A 361 (-3.7A)","0.83A","4hjoA-3nuuA:22.8","4hjoA-3nuuA:27.25"],["4HJO_A_AQ4A1001_1","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",6,"LEU A 192;VAL A 200;ALA A 213;MET A 266;GLY A 269;LEU A 318","AMP A 577 ( 4.3A);AMP A 577 (-4.3A);AMP A 577 (-3.4A);None;None;AMP A 577 (-4.8A)","0.49A","4hjoA-3nyoA:18.2","4hjoA-3nyoA:19.00"],["4HJO_A_AQ4A1001_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",10,"LEU A 726;VAL A 734;ALA A 751;LYS A 753;THR A 798;MET A 801;GLY A 804;LEU A 852;THR A 862;ASP A 863","03Q A   1 (-3.8A);03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.7A);03Q A   1 (-4.1A);None;03Q A   1 ( 3.9A);03Q A   1 (-4.4A);03Q A   1 (-3.3A);03Q A   1 (-4.0A)","0.75A","4hjoA-3pp0A:36.1","4hjoA-3pp0A:76.56"],["4HJO_A_AQ4A1001_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",10,"LEU A 726;VAL A 734;ALA A 751;THR A 798;MET A 801;GLY A 804;CYH A 805;LEU A 852;THR A 862;ASP A 863","03Q A   1 (-3.8A);03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.1A);None;03Q A   1 ( 3.9A);None;03Q A   1 (-4.4A);03Q A   1 (-3.3A);03Q A   1 (-4.0A)","0.62A","4hjoA-3pp0A:36.1","4hjoA-3pp0A:76.56"],["4HJO_A_AQ4A1001_1","3q4t","Homo sapiens","ACTIVIN RECEPTOR TYPE-2A","PF00069(Pkinase)",6,"VAL A 206;ALA A 217;THR A 267;GLY A 273;LEU A 329;ASP A 340","TAK A   2 ( 4.9A);TAK A   2 (-3.5A);TAK A   2 (-3.5A);TAK A   2 (-3.6A);TAK A   2 (-4.6A);None","0.57A","4hjoA-3q4tA:24.5","4hjoA-3q4tA:25.68"],["4HJO_A_AQ4A1001_1","3she","Homo sapiens","MAP KINASE-ACTIVATED PROTEIN KINASE 3","PF00069(Pkinase)",7,"LEU A  50;VAL A  58;ALA A  71;LYS A  73;MET A 121;LEU A 173;THR A 186","I85 A 350 (-3.7A);I85 A 350 (-4.9A);I85 A 350 (-3.3A);I85 A 350 (-2.8A);None;None;I85 A 350 ( 4.0A)","0.98A","4hjoA-3sheA:13.7","4hjoA-3sheA:23.40"],["4HJO_A_AQ4A1001_1","3she","Homo sapiens","MAP KINASE-ACTIVATED PROTEIN KINASE 3","PF00069(Pkinase)",7,"LEU A  50;VAL A  58;LYS A  73;MET A 121;LEU A 173;THR A 186;ASP A 187","I85 A 350 (-3.7A);I85 A 350 (-4.9A);I85 A 350 (-2.8A);None;None;I85 A 350 ( 4.0A);I85 A 350 (-3.3A)","1.08A","4hjoA-3sheA:13.7","4hjoA-3sheA:23.40"],["4HJO_A_AQ4A1001_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",8,"LEU A 423;VAL A 431;ALA A 443;LYS A 445;THR A 489;GLY A 495;CYH A 496;LEU A 543","PP2 A   1 (-4.1A);PP2 A   1 (-4.5A);PP2 A   1 (-3.2A);PP2 A   1 (-4.5A);PP2 A   1 (-3.3A);PP2 A   1 ( 4.2A);None;PP2 A   1 (-4.6A)","0.54A","4hjoA-3sxsA:30.7","4hjoA-3sxsA:30.47"],["4HJO_A_AQ4A1001_1","3ulz","Arabidopsis thaliana","BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1","PF00069(Pkinase)",8,"LEU A 295;VAL A 303;ALA A 315;LYS A 317;MET A 366;GLY A 369;LEU A 423;ASP A 434","None","0.82A","4hjoA-3ulzA:17.7","4hjoA-3ulzA:26.76"],["4HJO_A_AQ4A1001_1","3v5q","Homo sapiens","NT-3 GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 544;VAL A 552;ALA A 570;MET A 620;GLY A 623;LEU A 686","0F4 A 902 ( 4.2A);None;0F4 A 902 (-3.2A);None;0F4 A 902 (-3.4A);0F4 A 902 (-4.5A)","0.46A","4hjoA-3v5qA:24.1","4hjoA-3v5qA:29.94"],["4HJO_A_AQ4A1001_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",8,"LEU A  75;VAL A  83;ALA A  96;LYS A  98;MET A 147;GLY A 150;LEU A 198;ASP A 209","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);None;ANP A 401 ( 4.3A);ANP A 401 (-4.8A); MG A 402 (-3.2A)","0.61A","4hjoA-3wigA:10.2","4hjoA-3wigA:26.10"],["4HJO_A_AQ4A1001_1","3zbf","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","PF07714(Pkinase_Tyr)",6,"LEU A1951;VAL A1959;ALA A1978;MET A2029;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.51A","4hjoA-3zbfA:29.7","4hjoA-3zbfA:35.20"],["4HJO_A_AQ4A1001_1","3zfx","Homo sapiens","EPHRIN TYPE-B RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"ALA A 649;LYS A 651;THR A 697;MET A 700;GLY A 703;LEU A 751;ASP A 762","None","0.87A","4hjoA-3zfxA:32.0","4hjoA-3zfxA:36.39"],["4HJO_A_AQ4A1001_1","3zfx","Homo sapiens","EPHRIN TYPE-B RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"VAL A 633;ALA A 649;LYS A 651;THR A 697;MET A 700;GLY A 703;LEU A 751","None","0.73A","4hjoA-3zfxA:32.0","4hjoA-3zfxA:36.39"],["4HJO_A_AQ4A1001_1","4af3","Homo sapiens","AURORA KINASE B","PF00069(Pkinase)",6,"LEU A  83;VAL A  91;ALA A 104;LYS A 106;GLY A 160;LEU A 207","VX6 A 500 (-3.8A);VX6 A 500 ( 4.8A);VX6 A 500 (-3.4A);VX6 A 500 (-3.3A);VX6 A 500 (-3.3A);VX6 A 500 (-4.6A)","0.48A","4hjoA-4af3A:20.0","4hjoA-4af3A:25.07"],["4HJO_A_AQ4A1001_1","4at3","Homo sapiens","BDNF\/NT-3 GROWTH FACTORS RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 560;VAL A 568;ALA A 586;MET A 636;GLY A 639;LEU A 699","LTI A1839 ( 4.2A);None;LTI A1839 (-3.3A);None;LTI A1839 (-3.4A);LTI A1839 (-4.2A)","0.53A","4hjoA-4at3A:10.1","4hjoA-4at3A:30.70"],["4HJO_A_AQ4A1001_1","4aw5","Homo sapiens","EPHRIN TYPE-B RECEPTOR 4","PF07714(Pkinase_Tyr)",7,"VAL A 105;ALA A 121;LYS A 123;THR A 169;MET A 172;GLY A 175;LEU A 223","30K A1365 ( 4.6A);30K A1365 (-3.2A);30K A1365 (-3.8A);30K A1365 (-3.8A);None;30K A1365 (-3.5A);30K A1365 (-4.5A)","0.54A","4hjoA-4aw5A:30.7","4hjoA-4aw5A:32.94"],["4HJO_A_AQ4A1001_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",7,"VAL A 222;ALA A 233;LYS A 235;THR A 283;GLY A 289;LEU A 343;ASP A 354","TAK A1507 (-4.7A);TAK A1507 (-3.3A);TAK A1507 ( 4.5A);TAK A1507 (-3.6A);TAK A1507 (-3.5A);TAK A1507 (-4.7A);TAK A1507 (-3.5A)","0.69A","4hjoA-4c02A:25.2","4hjoA-4c02A:24.40"],["4HJO_A_AQ4A1001_1","4c0t","Candida albicans","LIKELY PROTEIN KINASE","PF00069(Pkinase)",7,"LEU A 246;VAL A 254;ALA A 267;GLY A 324;LEU A 371;THR A 381;ASP A 382","None","0.88A","4hjoA-4c0tA:21.5","4hjoA-4c0tA:16.32"],["4HJO_A_AQ4A1001_1","4f0i","Homo sapiens","HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 515;VAL A 523;ALA A 541;MET A 591;GLY A 594;LEU A 656","None","0.43A","4hjoA-4f0iA:29.5","4hjoA-4f0iA:31.75"],["4HJO_A_AQ4A1001_1","4fl3","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF00017(SH2);PF07714(Pkinase_Tyr)",7,"LEU A 377;VAL A 385;ALA A 400;LYS A 402;GLY A 454;LEU A 501;ASP A 512","ANP A 701 ( 4.6A);ANP A 701 (-4.1A);ANP A 701 (-3.3A);ANP A 701 (-2.7A);ANP A 701 ( 4.2A);ANP A 701 (-4.5A); MG A 702 ( 3.1A)","0.56A","4hjoA-4fl3A:32.8","4hjoA-4fl3A:21.42"],["4HJO_A_AQ4A1001_1","4fod","Homo sapiens","ALK TYROSINE KINASE RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A1122;VAL A1130;ALA A1148;MET A1199;GLY A1202;LEU A1256","0UV A1501 (-3.8A);0UV A1501 (-4.5A);0UV A1501 (-3.4A);None;0UV A1501 (-3.6A);0UV A1501 (-4.6A)","0.49A","4hjoA-4fodA:29.6","4hjoA-4fodA:31.40"],["4HJO_A_AQ4A1001_1","4gv1","Homo sapiens","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","PF00069(Pkinase);PF00433(Pkinase_C)",7,"LEU A 156;VAL A 164;ALA A 177;LYS A 179;GLY A 233;THR A 291;ASP A 292","0XZ A 501 ( 4.1A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 503 ( 2.8A);None;0XZ A 501 ( 4.1A);0XZ A 501 ( 3.4A)","0.97A","4hjoA-4gv1A:21.2","4hjoA-4gv1A:23.86"],["4HJO_A_AQ4A1001_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",8,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 211;LEU A 259;ASP A 270","None","0.70A","4hjoA-4hzsA:32.4","4hjoA-4hzsA:35.85"],["4HJO_A_AQ4A1001_1","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",7,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 211;LEU A 259","1G0 A 401 ( 4.5A);1G0 A 401 (-4.4A);1G0 A 401 (-3.6A);1G0 A 401 (-3.7A);1G0 A 401 (-3.2A);1G0 A 401 ( 4.5A);1G0 A 401 (-4.6A)","0.81A","4hjoA-4id7A:31.5","4hjoA-4id7A:35.00"],["4HJO_A_AQ4A1001_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"LEU A 273;VAL A 281;ALA A 293;LYS A 295;MET A 341;GLY A 344;LEU A 393;ASP A 404","0J9 A 601 (-4.0A);0J9 A 601 (-4.4A);0J9 A 601 (-3.3A);0J9 A 601 ( 4.7A);None;0J9 A 601 ( 4.1A);0J9 A 601 (-4.5A);0J9 A 601 (-3.1A)","0.55A","4hjoA-4k11A:29.3","4hjoA-4k11A:26.26"],["4HJO_A_AQ4A1001_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",8,"LEU A 273;VAL A 281;ALA A 293;LYS A 295;MET A 341;GLY A 344;LEU A 393;ASP A 404","VGG A 601 (-3.2A);VGG A 601 ( 3.5A);VGG A 601 (-3.5A);VGG A 601 (-3.8A);None;VGG A 601 ( 3.2A);VGG A 601 (-4.5A);VGG A 601 ( 4.7A)","0.99A","4hjoA-4lggA:29.0","4hjoA-4lggA:32.07"],["4HJO_A_AQ4A1001_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",8,"VAL A  36;ALA A  49;LYS A  51;THR A  95;MET A  98;GLY A 101;LEU A 150;ASP A 161","ANP A 401 (-4.5A);ANP A 401 (-3.1A);ANP A 401 (-2.9A);ANP A 401 (-3.8A);None;None;ANP A 401 (-4.8A); MG A 403 ( 3.1A)","0.60A","4hjoA-4m69A:26.0","4hjoA-4m69A:25.75"],["4HJO_A_AQ4A1001_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",7,"LEU A  46;VAL A  54;ALA A  67;LYS A  69;THR A 123;GLY A 128;LEU A 180","SIN A 401 ( 3.9A);None;SIN A 401 ( 3.7A);None;None;SIN A 401 (-3.5A);SIN A 401 ( 4.5A)","0.65A","4hjoA-4o38A:19.3","4hjoA-4o38A:21.70"],["4HJO_A_AQ4A1001_1","4oli","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"LEU A 595;VAL A 603;LYS A 642;THR A 687;GLY A 693;LEU A 741","2TT A1201 (-4.1A);2TT A1201 (-4.2A);2TT A1201 ( 4.6A);None;2TT A1201 (-3.5A);2TT A1201 (-4.1A)","0.52A","4hjoA-4oliA:28.7","4hjoA-4oliA:20.80"],["4HJO_A_AQ4A1001_1","4p2k","Homo sapiens","EPHRIN TYPE-A RECEPTOR 2","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"VAL A 627;ALA A 644;THR A 692;MET A 695;GLY A 698;LEU A 746","None","0.47A","4hjoA-4p2kA:30.4","4hjoA-4p2kA:34.68"],["4HJO_A_AQ4A1001_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",8,"LEU A  14;VAL A  22;ALA A  35;LYS A  37;THR A  81;MET A  84;GLY A  87;LEU A 136","ACP A1264 ( 4.5A);ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;ACP A1264 (-4.5A);None;ACP A1264 (-3.5A);ACP A1264 ( 4.8A)","0.64A","4hjoA-4ueuA:29.7","4hjoA-4ueuA:35.99"],["4HJO_A_AQ4A1001_1","4uy9","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9","PF00069(Pkinase)",7,"VAL A 158;ALA A 169;LYS A 171;GLY A 226;LEU A 275;THR A 293;ASP A 294","None","1.26A","4hjoA-4uy9A:27.5","4hjoA-4uy9A:31.64"],["4HJO_A_AQ4A1001_1","4wbo","Bos taurus","RHODOPSIN KINASE","PF00069(Pkinase);PF00615(RGS)",7,"LEU A 193;VAL A 201;ALA A 214;LYS A 216;MET A 267;GLY A 270;LEU A 321","ANW A 601 ( 4.0A);None;ANW A 601 (-3.4A);None;None;ANW A 601 ( 4.5A);ANW A 601 (-4.9A)","0.76A","4hjoA-4wboA:21.9","4hjoA-4wboA:20.40"],["4HJO_A_AQ4A1001_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",8,"LEU B 267;VAL B 275;ALA B 288;LYS B 290;THR B 334;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 (-3.3A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.42A","4hjoA-4xeyB:30.3","4hjoA-4xeyB:28.93"],["4HJO_A_AQ4A1001_1","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",9,"LEU A 408;VAL A 416;ALA A 428;THR A 474;MET A 477;GLY A 480;CYH A 481;LEU A 528;ASP A 539","None","0.96A","4hjoA-4xi2A:31.8","4hjoA-4xi2A:23.61"],["4HJO_A_AQ4A1001_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",8,"LEU A 408;VAL A 416;ALA A 428;LYS A 430;MET A 477;GLY A 480;LEU A 528;ASP A 539","746 A 702 (-3.8A);746 A 702 ( 4.3A);746 A 702 (-2.4A);746 A 702 (-3.7A);None;746 A 702 (-3.6A);746 A 702 (-4.4A);746 A 702 (-3.7A)","0.89A","4hjoA-4y93A:32.4","4hjoA-4y93A:24.28"],["4HJO_A_AQ4A1001_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",9,"LEU A 408;VAL A 416;ALA A 428;THR A 474;MET A 477;GLY A 480;CYH A 481;LEU A 528;ASP A 539","746 A 702 (-3.8A);746 A 702 ( 4.3A);746 A 702 (-2.4A);746 A 702 (-3.7A);None;746 A 702 (-3.6A);None;746 A 702 (-4.4A);746 A 702 (-3.7A)","0.74A","4hjoA-4y93A:32.4","4hjoA-4y93A:24.28"],["4HJO_A_AQ4A1001_1","4ysj","Eimeria tenella","CALMODULIN-LIKE DOMAIN PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",7,"LEU A  34;VAL A  42;ALA A  55;LYS A  57;THR A 105;GLY A 111;LEU A 158","ADP A 506 ( 3.8A);ADP A 506 (-4.3A);ADP A 506 (-3.3A);ADP A 506 (-2.4A);ADP A 506 ( 4.6A);None;ADP A 506 (-4.7A)","1.03A","4hjoA-4ysjA:19.3","4hjoA-4ysjA:22.74"],["4HJO_A_AQ4A1001_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",7,"LEU A 484;VAL A 492;ALA A 512;LYS A 514;GLY A 567;LEU A 630;ASP A 641","38O A1769 (-3.2A);38O A1769 (-4.5A);38O A1769 (-3.6A);38O A1769 ( 3.1A);38O A1769 (-3.4A);38O A1769 (-4.6A);38O A1769 (-4.0A)","0.89A","4hjoA-5a46A:29.4","4hjoA-5a46A:32.23"],["4HJO_A_AQ4A1001_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",7,"LEU A 599;VAL A 607;ALA A 625;LYS A 627;THR A 674;GLY A 680;LEU A 825","748 A1001 (-3.8A);748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 (-4.0A);748 A1001 (-3.2A);748 A1001 ( 4.0A);748 A1001 (-4.3A)","0.64A","4hjoA-5grnA:29.3","4hjoA-5grnA:31.25"],["4HJO_A_AQ4A1001_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",8,"LEU A 718;ALA A 743;MET A 793;GLY A 796;CYH A 797;LEU A 844;THR A 854;ASP A 855","6HJ A1101 ( 4.6A);6HJ A1101 (-3.1A);None;6HJ A1101 ( 4.5A);6HJ A1101 (-1.6A);6HJ A1101 ( 4.8A);6HJ A1101 (-3.9A);6HJ A1101 (-4.3A)","0.90A","4hjoA-5j9zA:35.2","4hjoA-5j9zA:99.38"],["4HJO_A_AQ4A1001_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",7,"LEU A 718;VAL A 726;ALA A 743;LYS A 745;MET A 793;GLY A 796;LEU A 844","6HJ A1101 ( 4.6A);6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);6HJ A1101 (-4.2A);None;6HJ A1101 ( 4.5A);6HJ A1101 ( 4.8A)","0.67A","4hjoA-5j9zA:35.2","4hjoA-5j9zA:99.38"],["4HJO_A_AQ4A1001_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",8,"LEU A 718;VAL A 726;ALA A 743;MET A 793;GLY A 796;CYH A 797;LEU A 844;THR A 854","6HJ A1101 ( 4.6A);6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);None;6HJ A1101 ( 4.5A);6HJ A1101 (-1.6A);6HJ A1101 ( 4.8A);6HJ A1101 (-3.9A)","0.82A","4hjoA-5j9zA:35.2","4hjoA-5j9zA:99.38"],["4HJO_A_AQ4A1001_1","5kbr","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 1","PF00069(Pkinase)",6,"VAL A 284;ALA A 297;LYS A 299;GLY A 350;LEU A 396;THR A 406","IPW A 601 (-4.2A);IPW A 601 (-3.5A);IPW A 601 (-4.5A);IPW A 601 ( 3.8A);IPW A 601 (-4.5A);IPW A 601 (-3.7A)","0.55A","4hjoA-5kbrA:22.4","4hjoA-5kbrA:26.55"],["4HJO_A_AQ4A1001_1","5lpy","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",7,"VAL A 897;ALA A 909;LYS A 911;MET A 959;GLY A 962;LEU A1016;ASP A1027","ATP A1200 ( 4.5A);ATP A1200 (-3.5A);ATP A1200 (-3.8A);None;ATP A1200 ( 4.0A);ATP A1200 (-4.6A);ATP A1200 (-4.1A)","0.85A","4hjoA-5lpyA:23.4","4hjoA-5lpyA:27.17"],["4HJO_A_AQ4A1001_1","5vil","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 5","no annotation",7,"LEU A 686;VAL A 694;ALA A 707;LYS A 709;GLY A 760;LEU A 810;ASP A 822","9E1 A1001 (-3.7A);9E1 A1001 ( 4.0A);9E1 A1001 (-3.5A);9E1 A1001 (-2.8A);9E1 A1001 (-3.4A);9E1 A1001 (-4.5A);9E1 A1001 (-3.6A)","1.08A","4hjoA-5vilA:15.9","4hjoA-5vilA:11.53"],["4HJO_A_AQ4A1001_1","5w5j","Homo sapiens","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","no annotation",8,"LEU A  24;VAL A  32;ALA A  45;LYS A  47;THR A  95;MET A  98;GLY A 101;LEU A 153","9WS A 401 ( 4.2A);9WS A 401 ( 4.6A);9WS A 401 (-3.3A);9WS A 401 (-3.3A);9WS A 401 (-3.2A);None;9WS A 401 ( 4.3A);9WS A 401 (-4.6A)","0.58A","4hjoA-5w5jA:23.8","4hjoA-5w5jA:27.75"],["4HJO_A_AQ4A1001_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",9,"LEU A 891;VAL A 899;ALA A 917;LYS A 919;THR A 963;GLY A 969;LEU A1017;THR A1027;ASP A1028","ANP A1201 (-4.1A);ANP A1201 (-4.4A);ANP A1201 (-3.3A);ANP A1201 (-3.8A);ANP A1201 (-3.9A);ANP A1201 ( 4.6A);ANP A1201 (-4.7A);ANP A1201 ( 4.9A); MG A1202 ( 3.0A)","0.61A","4hjoA-5wnoA:34.4","4hjoA-5wnoA:12.54"],["4HJO_A_AQ4A1001_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",7,"LEU A  33;VAL A  41;ALA A  54;LYS A  56;GLY A 105;LEU A 153;ASP A 164","ANP A 501 ( 3.8A);ANP A 501 (-4.4A);ANP A 501 ( 3.7A);ANP A 501 (-2.4A);ANP A 501 ( 4.0A);ANP A 501 (-4.6A); MG A 502 ( 3.1A)","0.57A","4hjoA-6ao5A:24.5","4hjoA-6ao5A:27.42"],["4HJO_A_AQ4A1001_1","6cz4","Homo sapiens","PROTEIN-TYROSINE KINASE 6","no annotation",8,"LEU A 197;VAL A 205;ALA A 217;LYS A 219;THR A 264;MET A 267;GLY A 270;LEU A 319","FKY A9001 (-4.1A);FKY A9001 ( 4.6A);FKY A9001 (-3.3A);None;FKY A9001 (-3.0A);None;FKY A9001 (-3.3A);FKY A9001 ( 4.9A)","0.84A","4hjoA-6cz4A:31.8","4hjoA-6cz4A:16.38"]]